头孢他啶/阿维巴坦
肺炎克雷伯菌
头孢他啶
美罗培南
微生物学
医学
生物
抗生素
粘菌素
细菌
铜绿假单胞菌
抗生素耐药性
大肠杆菌
遗传学
生物化学
基因
作者
Taryn Sleger,Eric Gangl,Petar Pop-Damkov,Kevin M. Krause,Peter J. Laud,Andrew M. Slee,Wright W. Nichols
标识
DOI:10.1080/1120009x.2017.1405609
摘要
Efficacies of ceftazidime-avibactam (4:1 w/w) and ceftazidime were tested against ceftazidime-susceptible (blaKPC-2-negative), and meropenem- and ceftazidime-resistant (blaKPC-2-positive), Klebsiella pneumoniae in a 52-h, multiple dose, abdominal abscess model in the rat. Efficacies corresponded to minimum inhibitory concentrations (MICs) measured in vitro and were consistent with drug exposures modelled from pharmacokinetics in infected animals. The ceftazidime, ceftazidime-avibactam and meropenem control treatments were effective in the rat abscess model against the susceptible strain, whereas only ceftazidime-avibactam was effective against K. pneumoniae harbouring blaKPC-2.
科研通智能强力驱动
Strongly Powered by AbleSci AI